Top Back to top

Abstract Topics

General topics

No. TOPIC
1 Haematopoietic stem cells
2 Stem cell mobilization, collection and engineering
3 CAR-based Cellular Therapy: preclinical
4 CAR-based Cellular Therapy: clinical
5 Cellular Therapy other than CARs
6 Gene Therapy
7 Experimental transplantation
8 New drug- and cell-based immune therapies
9 Non-haematopoietic stem cells
10 Regenerative medicine
11 Psychological issues
12 Pharmacology

Transplant-specific topics

no. TOPIC
13 Stem cell source
14 Stem cell donor
15 Graft-versus-host disease – preclinical and animal models
16 Graft-versus-host disease – clinical
17 Infectious complications
18 Non-infectious early complications
19 Non-infectious late effects & quality of life / fertility
20 Conditioning regimens
21 Minimal residual disease, tolerance, chimerism and immune reconstitution
22 Paediatric issues
23 Experimental stem cell transplantation

Disease-specific topics

no. TOPIC
24 Acute leukaemia
25 Aplastic anaemia
26 Autoimmune diseases
27 Chronic leukaemia and other myeloproliferative disorders
28 Granulocyte and osteoclast disorders
29 Haemoglobinopathy and inborn errors of metabolism
30 Immunodeficiency diseases and macrophages
31 Lymphoma
32 Multiple myeloma
33 Myelodysplastic syndromes
34 Solid tumours

Data Management Group

no. TOPIC
35 Data Management

Statistics

no. TOPIC
36 Statistics

Quality Management Group

no. TOPIC
37 Accreditation
38 Quality management
39 Regulatory issues
40 Sharing best quality practices

 

Care-specific topics

no. TOPIC
41 Care of the carer
42 Complementary therapies
43 Donor issues
44 Ethical issues
45 Impact of new therapies on patient care
46 Information and education
47 Management
48 Outpatient developments
49 Palliative care
50 Patient safety
51 Psycho-social issues
52 Protective care
53 Quality of life
54 Standards of care
55 Survivorship
56 Symptoms management
57 CAR-T or immune effector cells

 

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org